EGFRvIII Detection via Long-Range PCR Primer Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring glioblastoma multiforme (GBM) therapy, particularly in patients positive for the epithelial growth factor receptor vIII (EGFRvIII) gene, are limited by the difficulty in detecting and tracking EGFRvIII mutations due to varying deletion breakpoints, which complicates clinical management and treatment decision-making.
Innovation Solution
A method involving long-range polymerase chain reaction (PCR) amplification using specific primers spanning intron 1 and exon 8 of the EGFR gene to detect EGFRvIII deletions, allowing for the identification of deletion breakpoints and subsequent design of amplification primers to yield a 300-base pair PCR fragment, enabling the monitoring of EGFRvIII in genomic DNA and circulating tumor DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional PCR methods are used to detect EGFRvIII, then the detection process is simple, but the detection accuracy is low due to varying deletion breakpoints
Solution Approach 1:
The patent divides intron 1 into multiple segments with forward primers positioned at different locations. This segmentation allows the detection system to capture various deletion breakpoints that may occur at different positions within intron 1, thereby improving detection accuracy while managing complexity through systematic primer arrangement.
Solution Approach 2:
The detection method is designed to be universal for detecting EGFRvIII regardless of where the deletion breakpoint occurs within intron 1. By using multiple forward primers that can bind to different locations, the same assay system can detect various mutant variants, making the method multi-functional and broadly applicable.
2Measurement precision
If multiple forward primers are used to cover all possible deletion breakpoints, then the detection accuracy improves, but the complexity of the detection system increases
Solution Approach 1:
The patent divides intron 1 into multiple segments with forward primers positioned at different locations. This segmentation allows the detection system to capture various deletion breakpoints that may occur at different positions within intron 1, thereby improving detection accuracy while managing complexity through systematic primer arrangement.
Solution Approach 2:
The patent optimizes the spacing between forward primers (at least 5 kb apart) and adjusts primer positions to achieve optimal detection coverage. By carefully controlling the spatial parameters of primer placement, the system achieves comprehensive detection accuracy while minimizing the number of primers needed, thus balancing detection accuracy with system complexity.
3Measurement precision
If long-range PCR amplification is used to detect EGFRvIII, then the detection sensitivity improves, but the amplification time increases
Solution Approach 1:
The patent performs preliminary identification of deletion breakpoints using long-range PCR amplification across intron 1 before designing specific amplification primers. This preliminary action allows the system to characterize the mutation and then use optimized short-range PCR for rapid detection, reducing overall detection time while maintaining high sensitivity.
Solution Approach 2:
The patent uses long-range PCR amplification that spans the entire intron 1 region, which is larger than the minimum necessary to detect the mutation. This excessive action ensures that all possible deletion breakpoints are captured, maximizing detection sensitivity, while subsequent breakpoint identification allows for optimized shorter amplification in follow-up detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate detection and monitoring of EGFRvIII mutations in GBM patients, providing a non-invasive biomarker for tracking tumor dynamics and treatment efficacy, thereby improving clinical management and patient outcomes.
Implementation Method 1
long range polymerase chain reaction amplification of epithelial growth factor receptor vIII (EGFRvIII) gene
Data Source
AI summary
Methods and kits for detection and quantification of EGFRvIII in the peripheral blood for monitoring the therapy of a GBM patients.